UNLABELLED: Viral hepatitis is the leading cause of liver disease worldwide and can be caused by several agents, including hepatitis A (HAV), B (HBV), and C (HCV) virus. We employed multiplexed protein immune assays to identify biomarker signatures of viral hepatitis in order to define unique and common responses for three different acute viral infections of the liver. We performed multianalyte profiling, measuring the concentrations of 182 serum proteins obtained from acute HAV- (18), HBV- (18), and HCV-infected (28) individuals, recruited as part of a hospital-based surveillance program in Cairo, Egypt. Virus-specific biomarker signatures were identified and validation was performed using a unique patient population. A core signature of 46 plasma proteins was commonly modulated in all three infections, as compared to healthy controls. Principle component analysis (PCA) revealed a host response based upon 34 proteins, which could distinguish HCV patients from HAV- and HBV-infected individuals or healthy controls. When HAV and HBV groups were compared directly, 34 differentially expressed serum proteins allowed the separation of these two patient groups. A validation study was performed on an additional 111 patients, confirming the relevance of our initial findings, and defining the 17 analytes that reproducibly segregated the patient populations. CONCLUSIONS: This combined discovery and biomarker validation approach revealed a previously unrecognized virus-specific induction of host proteins. The identification of hepatitis virus specific signatures provides a foundation for functional studies and the identification of potential correlates of viral clearance.
UNLABELLED: Viral hepatitis is the leading cause of liver disease worldwide and can be caused by several agents, including hepatitis A (HAV), B (HBV), and C (HCV) virus. We employed multiplexed protein immune assays to identify biomarker signatures of viral hepatitis in order to define unique and common responses for three different acute viral infections of the liver. We performed multianalyte profiling, measuring the concentrations of 182 serum proteins obtained from acute HAV- (18), HBV- (18), and HCV-infected (28) individuals, recruited as part of a hospital-based surveillance program in Cairo, Egypt. Virus-specific biomarker signatures were identified and validation was performed using a unique patient population. A core signature of 46 plasma proteins was commonly modulated in all three infections, as compared to healthy controls. Principle component analysis (PCA) revealed a host response based upon 34 proteins, which could distinguish HCV patients from HAV- and HBV-infected individuals or healthy controls. When HAV and HBV groups were compared directly, 34 differentially expressed serum proteins allowed the separation of these two patient groups. A validation study was performed on an additional 111 patients, confirming the relevance of our initial findings, and defining the 17 analytes that reproducibly segregated the patient populations. CONCLUSIONS: This combined discovery and biomarker validation approach revealed a previously unrecognized virus-specific induction of host proteins. The identification of hepatitis virus specific signatures provides a foundation for functional studies and the identification of potential correlates of viral clearance.
Authors: Angela Filomena; Frank Pessler; Manas K Akmatov; Gérard Krause; Darragh Duffy; Barbara Gärtner; Markus Gerhard; Matthew L Albert; Thomas O Joos; Nicole Schneiderhan-Marra Journal: High Throughput Date: 2017-10-30
Authors: Jacqueline Estevez; Vincent L Chen; Ondrej Podlaha; Biao Li; An Le; Philip Vutien; Ellen T Chang; Yael Rosenberg-Hasson; Zhaoshi Jiang; Stefan Pflanz; Dongliang Ge; Anuj Gaggar; Mindie H Nguyen Journal: Sci Rep Date: 2017-09-19 Impact factor: 4.379
Authors: Lluis Quintana-Murci; Darragh Duffy; Antonio Rausell; Barthelemy Caron; Etienne Patin; Maxime Rotival; Bruno Charbit; Matthew L Albert Journal: Genome Med Date: 2022-03-09 Impact factor: 11.117
Authors: Jérémie Decalf; Kristin V Tarbell; Armanda Casrouge; Jeffrey D Price; Grace Linder; Estelle Mottez; Philippe Sultanik; Vincent Mallet; Stanislas Pol; Darragh Duffy; Matthew L Albert Journal: EMBO Mol Med Date: 2016-06-01 Impact factor: 12.137
Authors: Cécile Alanio; Francesco Nicoli; Philippe Sultanik; Tobias Flecken; Brieuc Perot; Darragh Duffy; Elisabetta Bianchi; Annick Lim; Emmanuel Clave; Marit M van Buuren; Aurélie Schnuriger; Kerstin Johnsson; Jeremy Boussier; Antoine Garbarg-Chenon; Laurence Bousquet; Estelle Mottez; Ton N Schumacher; Antoine Toubert; Victor Appay; Farhad Heshmati; Robert Thimme; Stanislas Pol; Vincent Mallet; Matthew L Albert Journal: Elife Date: 2015-11-14 Impact factor: 8.140